NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE89972 Query DataSets for GSE89972
Status Public on May 24, 2017
Title Molecular phenotyping empowers drug discovery: a proof-of-concept study
Organism Homo sapiens
Experiment type Expression profiling by high throughput sequencing
Summary Today, novel candidate therapeutics are identified in an environment which is intrinsically different from the clinical context in which they are ultimately evaluated. We present a strategy that allows biological relevance to be assessed in the early stages of drug discovery. Using molecular phenotyping and an in vitro model of diabetic cardiomyopathy, we show that by quantifying pathway reporter gene expression, molecular phenotyping can cluster compounds based on pathway profiles and dissect associations between pathway activities and disease phenotypes simultaneously. Molecular phenotyping identified a class of calcium-signaling modulators that can reverse disease-regulated pathways and phenotypes, which was validated by structurally distinct compounds of relevant classes. The technique was applicable to compounds with a range of binding specificities and detected false-positive hits missed by classical phenotypic assays. Our results advocate application of molecular phenotyping in drug discovery, promoting biological relevance as a key selection criterion early in the drug development cascade.
 
Overall design Molecular Phenotyping after 12h of compound treatment; A total number of 80 compounds were profiled with molecular phenotyping, along with four control conditions: media control, which represents the healthy status; GEC, which mimicks the stress condition in T2D patients; BM, a cocktail of bosentan, an enthothelin receptor antagonist, and mifepristone, a progesterone receptor antagonist, which is supposed to reverse the disease phenotype; and GEC+BM, which mimicks a successful reversal of the phenotype from the stress condtion. The compounds were screened on six plates (A-F), with one replicate for each compound and one replicate for each control on each plate. Some compounds that failed the first screening run were tested in two cherry-picking replication plates (R1 and R2). Calcium channel inhibitor hits were then tested in phenotypic high-content microscopy assays with two or three biological replicates each.
 
Contributor(s) Kueng E, Certa U, Ebeling M, Zhang JD
Citation(s) 28434878
Submission date Nov 17, 2016
Last update date May 15, 2019
Contact name Jitao David Zhang
E-mail(s) jitao_david.zhang@roche.com
Phone +41616886251
Organization name F. Hoffmann-La Roche
Department Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel
Lab Pharmaceutical Sciences
Street address Grenzacherstrasse 124
City Basel
ZIP/Postal code 4070
Country Switzerland
 
Platforms (1)
GPL17301 Ion Torrent PGM (Homo sapiens)
Samples (104)
GSM2394470 Plate F1; Treatment RO0611790-000-012
GSM2394471 Plate F1; Treatment RO0470203-000-017
GSM2394472 Plate F1; Treatment RO0475819-001-001
Relations
BioProject PRJNA354350
SRA SRP093740

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE89972_cardiomyopathy-MolecularPhenotyping-201611.gct.gz 206.3 Kb (ftp)(http) GCT
SRA Run SelectorHelp
Raw data are available in SRA
Processed data are available on Series record

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap